D&D Pharmatech Signs Obesity Treatment Research Contract with Pfizer
D&D Pharmatech announced on the 16th that it has signed a research service contract with Pfizer in the United States for the development of an oral peptide dual agonist (obesity treatment) formulation.
Hot Picks Today
"With This Certificate, Even Those in Their 60s...
- Popcorn Container Craze at Theaters Sparks Sell-Out Frenzy, Emerges as New Reven...
- When His Father Suddenly Collapsed Before His Eyes... 13-Year-Old Son Preserves ...
- Female Game Caster Makes Bold Move After Criticism Over "Short Skirt" on Broadca...
- "Quit Office Job to Earn Over 200 Million Won a Year"… Chinese Woman in Her 30s...
The contract amount is equivalent to 42.64% of last year’s sales. The contract period runs until November 30, 2026.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
!["They Said It Was 'Delicious' Milk... Is the 'List of Fake Milk Products in Korea' for Real? [Matjal X-File]"](https://cwcontent.asiae.co.kr/asiaresize/307/2023072413274517286_1690172865.jpg)
